What’s best for stage III NSCLC? Local control w definitive radiation or an R1 surgical resection?
@GraceHaMD presents NCDB data at #AATS2026 showing a long-term survival benefit to surgery over XRT, even with +margins.
⬆️ survival for R1+ pts as systematic therapies improve
Honored to contribute to the discussion on surgical considerations following neoadjuvant therapy. As treatment paradigms evolve, so must our approach in the OR.
Happy belated National Women Physicians Day from the Women in Thoracic Surgery. We recognize the women physicians whose dedication strengthens our specialty every day. #WTS
What a strong opening to #STS2026! Day 1 brought celebrated award recipients, groundbreaking science, and inspiring voices—setting the tone for an incredible weekend ahead. 👏✨ #CTsurgery
Great session Challenging Lung Dogma moderated by @IanCBostock1 and @jdoningtonmd@maraantonoff on surgical resection in stage IV
@nchudgar on extending our criteria for surgical resectability, converting borderline resectable to resectable and study data from MDT-Bridge
Pneumonectomy for T4N0-2 tumors or a PACIFIC chemoXRT and immunotherapy regimen?
NCDB data presented by @GraceHaMD show survival benefit to pneumonectomy in propensity matched cohorts.
Best outcomes in women, left side disease, and w neoadjuvant treatment.
#STS2026
Interesting data from @GraceHaMD@MontefioreNYC on mutations and PD-L1 in black and Hispanic NSCLC pts, underrepresented in trials.
High rates of EGFR in Asian and Hispanic pts. EGFR mutations in black pts are often non-sensitizing and may explain differences in survival.
Even with generous leave policies, pregnant surgeons across countries report the same fears: being seen as weak, burdensome, or uncommitted. Surgery’s masculine norms persist.
https://t.co/PJ5kn0wigQ